Shots:

• Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones
• Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients
• Tusk’s Spinout Black Belt Therapeutics- will hold the development of a remaining portfolio of immune-oncology targets excluding novel Ab

Ref: Tusk Therapeutics | Image: Roche